CRDF Cardiff Oncology, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1213037 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.6%
TTM net income YoY25.3%
TTM EPS YoY31.6%
Revenue 3-yr CAGR6.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-7,068.2%
Net margin-6,735.2%
FCF margin—
EBITDA margin-7,005.5%
Returns
ROE-97.9%
ROA-75.2%
ROIC (approx.)-114.1%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets22.8%
Debt / equity0.00x
Current ratio4.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.06x
Accruals ratio4.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $593,000 | $683,000 |
| R&D expense | $35.33M | $36.85M |
| SG&A expense | $14.22M | $12.48M |
| Operating income | -$48.96M | -$48.65M |
| Pretax income | -$45.85M | -$45.43M |
| Income tax | $0 | $0 |
| Net income | -$45.85M | -$45.43M |
| EBITDA | -$48.60M | -$48.25M |
| EPS (basic) | -0.69 | -0.95 |
| EPS (diluted) | -0.69 | -0.95 |
| Weighted avg. shares (diluted) | 66.84M | 47.65M |
| Balance sheet | ||
| Cash & equivalents | $17.47M | $51.47M |
| Short-term investments | $40.83M | $40.28M |
| Receivables | $182,000 | $773,000 |
| Current assets | $60.13M | $95.05M |
| PP&E, net | $578,000 | $898,000 |
| Total assets | $61.88M | $97.19M |
| Current liabilities | $16.39M | $13.43M |
| Total liabilities | $16.50M | $14.24M |
| Shareholders' equity | $45.39M | $82.95M |
| Shares outstanding | 68.31M | 66.52M |
| Cash flow statement | ||
| Operating cash flow | -$37.92M | -$37.69M |
| Capital expenditure | $44,000 | $80,000 |
| Free cash flow | -$37.97M | -$37.77M |
| Investing cash flow | $1.34M | $13.73M |
| Financing cash flow | $2.58M | $53.78M |
| Depreciation & amortization | $364,000 | $404,000 |
| Stock-based compensation | $5.69M | $4.76M |
Free plan shows the latest 2 periods; Pro shows all 25 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.